Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1258020

The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding


Šimičević, Livija; Slišković, Ana Marija; Vrkić Kirhmajer, Majda; Ganoci, Lana; Holik, Hrvoje; Samardžić, Jure; Božina, Tamara
The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding // Pharmaca, 52 (2022), Suppl 2
Opatija, Hrvatska, 2022. str. 141-141 (poster, domaća recenzija, sažetak, znanstveni)


CROSBI ID: 1258020 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding

Autori
Šimičević, Livija ; Slišković, Ana Marija ; Vrkić Kirhmajer, Majda ; Ganoci, Lana ; Holik, Hrvoje ; Samardžić, Jure ; Božina, Tamara

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Pharmaca, 52 (2022), Suppl 2 / - , 2022, 141-141

Skup
10. hrvatski kongres farmakologije ; 1. hrvatski kongres kliničke farmakologije s međunarodnim sudjelovanjem = 10th Croatian Congress of Pharmacology ; 1st Croatian Congress of Clinical Pharmacology and Therapeutics with International Participation

Mjesto i datum
Opatija, Hrvatska, 22.09.2022. - 25.09.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
adverse events ; pharmacogenetics ; rivaroxaban ; risk factors

Sažetak
Introduction: Rivaroxaban has large interindividual trough concentration variability affecting its efficacy and safety, especially bleeding events. This variability could be associated with age, liver and kidney function, concomitant illness and therapy, and pharmacogenetic predisposition. Rivaroxaban is a substrate of ABCB1 and ABCG2 transporters, and CYP2J2, CYP3A4/5 enzymes. The polymorphisms of these genes may affect the pharmacokinetics of rivaroxaban and its safety profile. Aim of the study is to evaluate role of pharmacogenetics as possible risk factor for rivaroxaban-associated bleeding in patients treated for cardiovascular diseases. Patients and Methods: Presented data are part of the larger prospective nested case-control study “Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction”. Clinical and laboratory data were collected. Pharmacogenetic analyses were performed using specific TaqMan® DME and SNP Assays on 7500 Real- Time PCR System for genotyping of CYP3A4*1B*22, CYP3A5*3, CYP2J2*7, c.1331- 2201T>C, ABCB1 (c.1236C>T, c.2482-2236G>A, c.2677G>T/A, c.3435C>T) and ABCG2 (c.421C>A) variants. For drug-drug interactions (DDI), The Lexicomp® Clinical Decision Support System was applied. Results: Sixteen patients (median age 73 years, range 61-80) with rivaroxaban-associated bleeding: gastrointestinal (N=9), epistaxis (N=5), haematuria (N=1) and gynaecological (N=1) were analysed. In 9/16 DDI with increased bleeding risk were found. Two patients had eGFR>90, while six patients had eGFR<60. Only three patients who experienced bleeding did not have any of investigated risk factors including gene variants. Conclusions: Our data suggest a possible role of pharmacogenetic and clinical factors and their interactions in predicting bleeding on rivaroxaban treatment. These findings indicate the need for further comprehensive research.

Izvorni jezik
Engleski

Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti, Farmacija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)



POVEZANOST RADA


Projekti:
HRZZ-UIP-2020-02-8189 - Uloga farmakogenomike u predviđanju nuspojava kardiovaskularnih lijekova (PGx-CardioDrug) (Božina, Tamara, HRZZ - 2020-02) ( CroRIS)

Ustanove:
Medicinski fakultet, Zagreb,
Opća bolnica "Dr. Josip Benčević",
Klinički bolnički centar Zagreb

Poveznice na cjeloviti tekst rada:

hdf-pharma.mef.hr

Citiraj ovu publikaciju:

Šimičević, Livija; Slišković, Ana Marija; Vrkić Kirhmajer, Majda; Ganoci, Lana; Holik, Hrvoje; Samardžić, Jure; Božina, Tamara
The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding // Pharmaca, 52 (2022), Suppl 2
Opatija, Hrvatska, 2022. str. 141-141 (poster, domaća recenzija, sažetak, znanstveni)
Šimičević, L., Slišković, A., Vrkić Kirhmajer, M., Ganoci, L., Holik, H., Samardžić, J. & Božina, T. (2022) The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding. U: Pharmaca, 52 (2022), Suppl 2.
@article{article, author = {\v{S}imi\v{c}evi\'{c}, Livija and Sli\v{s}kovi\'{c}, Ana Marija and Vrki\'{c} Kirhmajer, Majda and Ganoci, Lana and Holik, Hrvoje and Samard\v{z}i\'{c}, Jure and Bo\v{z}ina, Tamara}, year = {2022}, pages = {141-141}, keywords = {adverse events, pharmacogenetics, rivaroxaban, risk factors}, title = {The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding}, keyword = {adverse events, pharmacogenetics, rivaroxaban, risk factors}, publisherplace = {Opatija, Hrvatska} }
@article{article, author = {\v{S}imi\v{c}evi\'{c}, Livija and Sli\v{s}kovi\'{c}, Ana Marija and Vrki\'{c} Kirhmajer, Majda and Ganoci, Lana and Holik, Hrvoje and Samard\v{z}i\'{c}, Jure and Bo\v{z}ina, Tamara}, year = {2022}, pages = {141-141}, keywords = {adverse events, pharmacogenetics, rivaroxaban, risk factors}, title = {The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding}, keyword = {adverse events, pharmacogenetics, rivaroxaban, risk factors}, publisherplace = {Opatija, Hrvatska} }




Contrast
Increase Font
Decrease Font
Dyslexic Font